Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

740 related articles for article (PubMed ID: 25712124)

  • 1. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.
    Prabhu VV; Allen JE; Dicker DT; El-Deiry WS
    Cancer Res; 2015 Apr; 75(7):1423-32. PubMed ID: 25712124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.
    Allen JE; Krigsfeld G; Patel L; Mayes PA; Dicker DT; Wu GS; El-Deiry WS
    Mol Cancer; 2015 May; 14():99. PubMed ID: 25927855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects.
    Allen JE; Krigsfeld G; Mayes PA; Patel L; Dicker DT; Patel AS; Dolloff NG; Messaris E; Scata KA; Wang W; Zhou JY; Wu GS; El-Deiry WS
    Sci Transl Med; 2013 Feb; 5(171):171ra17. PubMed ID: 23390247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors.
    Prabhu VV; Lulla AR; Madhukar NS; Ralff MD; Zhao D; Kline CLB; Van den Heuvel APJ; Lev A; Garnett MJ; McDermott U; Benes CH; Batchelor TT; Chi AS; Elemento O; Allen JE; El-Deiry WS
    PLoS One; 2017; 12(8):e0180541. PubMed ID: 28767654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of DNA-PKcs as a primary resistance factor of TIC10 in hepatocellular carcinoma cells.
    Cheng L; Liu YY; Lu PH; Peng Y; Yuan Q; Gu XS; Jin Y; Chen MB; Bai XM
    Oncotarget; 2017 Apr; 8(17):28385-28394. PubMed ID: 28415690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The preclinical evaluation of TIC10/ONC201 as an anti-pancreatic cancer agent.
    Zhang Q; Wang H; Ran L; Zhang Z; Jiang R
    Biochem Biophys Res Commun; 2016 Aug; 476(4):260-266. PubMed ID: 27233611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment.
    Wagner J; Kline CL; Zhou L; Campbell KS; MacFarlane AW; Olszanski AJ; Cai KQ; Hensley HH; Ross EA; Ralff MD; Zloza A; Chesson CB; Newman JH; Kaufman H; Bertino J; Stein M; El-Deiry WS
    J Clin Invest; 2018 Jun; 128(6):2325-2338. PubMed ID: 29533922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells.
    Talekar MK; Allen JE; Dicker DT; El-Deiry WS
    Cell Cycle; 2015 Aug; 14(15):2422-8. PubMed ID: 26030065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy.
    Wang J; Wang H; Wang LY; Cai D; Duan Z; Zhang Y; Chen P; Zou JX; Xu J; Chen X; Kung HJ; Chen HW
    Cell Death Differ; 2016 Nov; 23(11):1886-1896. PubMed ID: 27612013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of FOXO3a reverses 5-Fluorouracil resistance in human breast cancer cells.
    Song Y; Lu M; Qiu H; Yin J; Luo K; Zhang Z; Jia X; Zheng G; Liu H; He Z
    Exp Mol Pathol; 2018 Aug; 105(1):57-62. PubMed ID: 29856982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.
    Karpel-Massler G; Bâ M; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD
    Oncotarget; 2015 Nov; 6(34):36456-71. PubMed ID: 26474387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10.
    Allen JE; Prabhu VV; Talekar M; van den Heuvel AP; Lim B; Dicker DT; Fritz JL; Beck A; El-Deiry WS
    Cancer Res; 2015 Apr; 75(8):1668-74. PubMed ID: 25681273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.
    Wagner J; Kline CL; Ralff MD; Lev A; Lulla A; Zhou L; Olson GL; Nallaganchu BR; Benes CH; Allen JE; Prabhu VV; Stogniew M; Oster W; El-Deiry WS
    Cell Cycle; 2017 Oct; 16(19):1790-1799. PubMed ID: 28489985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecule ONC201 inhibits HIV-1 replication in macrophages via FOXO3a and TRAIL.
    Zhao R; Li Y; Gorantla S; Poluektova LY; Lin H; Gao F; Wang H; Zhao J; Zheng JC; Huang Y
    Antiviral Res; 2019 Aug; 168():134-145. PubMed ID: 31158413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases.
    Kline CL; Van den Heuvel AP; Allen JE; Prabhu VV; Dicker DT; El-Deiry WS
    Sci Signal; 2016 Feb; 9(415):ra18. PubMed ID: 26884600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small Molecular TRAIL Inducer ONC201 Induces Death in Lung Cancer Cells: A Preclinical Study.
    Feng Y; Zhou J; Li Z; Jiang Y; Zhou Y
    PLoS One; 2016; 11(9):e0162133. PubMed ID: 27626799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent.
    Allen JE; Crowder RN; El-Deiry WS
    PLoS One; 2015; 10(11):e0143082. PubMed ID: 26580220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR inhibition sensitizes ONC201-induced anti-colorectal cancer cell activity.
    Jin ZZ; Wang W; Fang DL; Jin YJ
    Biochem Biophys Res Commun; 2016 Sep; 478(4):1515-20. PubMed ID: 27565731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
    Prabhu VV; Morrow S; Rahman Kawakibi A; Zhou L; Ralff M; Ray J; Jhaveri A; Ferrarini I; Lee Y; Parker C; Zhang Y; Borsuk R; Chang WI; Honeyman JN; Tavora F; Carneiro B; Raufi A; Huntington K; Carlsen L; Louie A; Safran H; Seyhan AA; Tarapore RS; Schalop L; Stogniew M; Allen JE; Oster W; El-Deiry WS
    Neoplasia; 2020 Dec; 22(12):725-744. PubMed ID: 33142238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXM1-Induced PRX3 Regulates Stemness and Survival of Colon Cancer Cells via Maintenance of Mitochondrial Function.
    Song IS; Jeong YJ; Jeong SH; Heo HJ; Kim HK; Bae KB; Park YH; Kim SU; Kim JM; Kim N; Ko KS; Rhee BD; Han J
    Gastroenterology; 2015 Oct; 149(4):1006-16.e9. PubMed ID: 26091938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.